CDK Stock Recent News

AUSTIN, Texas--(BUSINESS WIRE)-- #CDKGlobal--CDK, the leading automotive retail software provider, today announced the extension of its agreement with Sonic Automotive, Inc. (NYSE: SAH), one of the nation's largest automotive and powersports retailers, to provide its dealerships with the CDK Dealer Management System (DMS) and its Dealership Xperience Modern Retail Suite, a set of powerful software tools that connects the consumer-to-dealer buying journey into a single, unified transaction for a more satisfy.

CDK cyberattack results in operational chaos in the auto retail industry, forcing dealerships into manual mode and sparking industry-wide cybersecurity reassessments.

Group 1 Automotive Inc. GPI, -0.36% said Monday the cyber-attack at software provider CDK Global last week has disrupted its business applications and processes at U.S. operations that rely on CDK's dealers' systems. “In response, the company immediately activated its cyber incident response procedures and proactively took measures to protect and isolate its systems from CDK's platform,” Houston-based Group 1 said in a statement.

HOUSTON , June 24, 2024 /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), a Fortune 300 automotive retailer with 202 dealerships located in the U.S. and U.K., today announced that the cybersecurity incident recently experienced by third-party software provider, CDK Global LLC ("CDK"), has disrupted Group 1's business applications and processes in its U.S. operations that rely on CDK's dealers' systems.  In response, the Company immediately activated its cyber incident response procedures and proactively took measures to protect and isolate its systems from CDK's platform.

The firm says on its website that its software is used by nearly 15,000 car dealers

AUSTIN, Texas--(BUSINESS WIRE)--Top Publicly Held Dealer Group 1 Automotive Goes All-In on Innovation with CDK Dealership Xperience Platform.

-- Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities -- -- Early signal of clinical activity includes compelling biomarker reductions correlated with BLU-222 exposure -- CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.

Here is how CDK Global (CDK) and Gree (GREZF) have performed compared to their sector so far this year.

CDK Global (CDK) delivered earnings and revenue surprises of 5.41% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?